Tirbanibulin Ointment Eradicates HPV-57 (+) Periungual Squamous Cell Carcinoma
Main Article Content
Keywords
Skin Cancer
Abstract
N/A
References
pathophysiology revisited. J Eur Acad Dermatol Venereol. 2017;31 Suppl 2:5-7.
doi:10.1111/jdv.14151
2. Smolinski MP, Bu Y, Clements J, et al. Discovery of Novel Dual Mechanism of
Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-
361). J Med Chem. 2018;61(11):4704-4719. doi:10.1021/acs.jmedchem.8b00164
3. Smolinski MP, Bu Y, Clements J, et al. Discovery of Novel Dual Mechanism of
Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-
361). J Med Chem. 2018;61(11):4704-4719. doi:10.1021/acs.jmedchem.8b00164
4. Blauvelt A, Kempers S, Forman S, Lain E, Bruce S. Tirbanibulin Ointment 1%, a
Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling , for the
Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies. J
of Skin. 2020;4(5):s63-s63. doi:10.25251/skin.4.supp.62
5. Moore AY, Moore S. Topical tirbanibulin eradication of periungual squamous cell
carcinoma. JAAD Case Reports. 2021;14:101-103. doi:10.1016/j.jdcr.2021.06.013
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.